Drugs that inhibit gastric acid secretion may alter the course of inflammatory bowel disease

Alimentary Pharmacology and Therapeutics

Volumn 36, Issue 3, 2012, Pages 239-247

  Juillerat, P ^a,b   Schneeweiss, S ^c   Cook, E F ^d   Ananthakrishnan, A N ^a   Mogun, H ^c   Korzenik, J R ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF BERN   (Switzerland)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AZATHIOPRINE; BUDESONIDE; CIMETIDINE; CIPROFLOXACIN; CLARITHROMYCIN; ESOMEPRAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; INFLIXIMAB; LANSOPRAZOLE; LEVOFLOXACIN; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METRONIDAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PREDNISONE; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; SALAZOSULFAPYRIDINE;

ADULT; ARTICLE; CANADA; COHORT ANALYSIS; CONTROLLED STUDY; CROHN DISEASE; ENTERITIS; FEMALE; FOLLOW UP; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPENSITY SCORE; RISK ASSESSMENT; STOMACH ACID SECRETION; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BRITISH COLUMBIA; COHORT STUDIES; FEMALE; GASTRIC ACID; GASTRIC ACIDITY DETERMINATION; GASTRIC JUICE; HISTAMINE H2 ANTAGONISTS; HUMANS; HYDROGEN-ION CONCENTRATION; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; PROTON PUMP INHIBITORS; YOUNG ADULT;

EID: 84863323834     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2012.05173.x     Document Type: Article

References (37)

1. Baumgart DC, Carding SR,. Inflammatory bowel disease: cause and immunobiology. Lancet 2007; 369: 1627-40. (Pubitemid 46722636)
2. Lassen A, Hallas J, Schaffalitzky De Muckadell OB,. Use of anti-secretory medication: a population-based cohort study. Aliment Pharmacol Ther 2004; 20: 577-83. (Pubitemid 39243903)
3. Mottet C, Juillerat P, Pittet V, et al,. Upper gastrointestinal Crohn's disease. Digestion 2007; 76: 136-40. (Pubitemid 351194908)
4. Yang YX, Metz DC,. Safety of proton pump inhibitor exposure. Gastroenterology 2010; 139: 1115-27.
5. Thorens J, Froehlich F, Schwizer W, et al,. Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study. Gut 1996; 39: 54-9. (Pubitemid 26239105)
6. Kanno T, Matsuki T, Oka M, et al,. Gastric acid reduction leads to an alteration in lower intestinal microflora. Biochem Biophys Res Commun 2009; 381: 666-70.
7. Elenkov IJ, Webster E, Papanicolaou DA, Fleisher TA, Chrousos GP, Wilder RL,. Histamine potently suppresses human IL-12 and stimulates IL-10 production via H2 receptors. J Immunol 1998; 161: 2586-93. (Pubitemid 28397078)
8. Jutel M, Akdis M, Akdis CA,. Histamine, histamine receptors and their role in immune pathology. Clin Exp Allergy 2009; 39: 1786-800.
9. Nielsen HJ, Svenningsen A, Moesgaard F, et al,. Ranitidine improves certain cellular immune responses in asymptomatic HIV-infected individuals. J Acquir Immune Defic Syndr 1991; 4: 577-84.
10. Wang J, Su B, Ding Z, Du X, Wang B,. Cimetidine enhances immune response of HBV DNA vaccination via impairment of the regulatory function of regulatory T cells. Biochem Biophys Res Commun 2008; 372: 491-6.
11. Wandall JH,. Effects of omeprazole on neutrophil chemotaxis, super oxide production, degranulation, and translocation of cytochrome b-245. Gut 1992; 33: 617-21.
12. Suzuki M, Mori M, Miura S, et al,. Omeprazole attenuates oxygen-derived free radical production from human neutrophils. Free Radical Biol Med 1996; 21: 727-31. (Pubitemid 26331104)
13. Zedtwitz-Liebenstein K, Wenisch C, Patruta S, Parschalk B, Daxbock F, Graninger W,. Omeprazole treatment diminishes intra- and extracellular neutrophil reactive oxygen production and bactericidal activity. Crit Care Med 2002; 30: 1118-22. (Pubitemid 34508037)
14. Alkim H, Unal S, Okur H, Imir T,. Omeprazole inhibits natural killer cell functions. Dig Dis Sci 2008; 53: 347-51. (Pubitemid 351170011)
15. Yoshida N, Yoshikawa T, Tanaka Y, et al,. A new mechanism for anti-inflammatory actions of proton pump inhibitors-inhibitory effects on neutrophil-endothelial cell interactions. Aliment Pharmacol Ther 2000; 14: 74-81. (Pubitemid 30199109)
16. Neal KR, Scott HM, Slack RC, Logan RF,. Omeprazole as a risk factor for Campylobacter gastroenteritis: case-control study. BMJ 1996; 312: 414-5.
17. Garcia Rodriguez LA, Ruigomez A, Panes J,. Use of acid-suppressing drugs and the risk of bacterial gastroenteritis. Clin Gastroenterol Hepatol 2007; 5: 1418-23. (Pubitemid 350181606)
18. Aseeri M, Schroeder T, Kramer J, Zackula R,. Gastric acid suppression by proton pump inhibitors as a risk factor for Clostridium difficile-associated diarrhea in hospitalized patients. Am J Gastroenterol 2008; 103: 2308-13.
19. Laheij RJF, Sturkenboom MCJM, Hassing R-J, Dieleman J, Stricker BHC, Jansen JBMJ,. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004; 292: 1955-60. (Pubitemid 39411203)
20. British Columbia Linked Health Database and UBC Centre for Health Services & Policy Research (CHSPR). Available at: and. Accessed May 14, 2012.
21. Bernstein CN, Blanchard JF, Rawsthorne P, Wajda A,. Epidemiology of Crohn's disease and ulcerative colitis in a central Canadian province: a population-based study. Am J Epidemiol 1999; 149: 916-24. (Pubitemid 29230706)
22. Wolters FL, Russel MG, Sijbrandij J, et al,. Phenotype at diagnosis predicts recurrence rates in Crohn's disease. Gut 2006; 55: 1124-30. (Pubitemid 44085679)
23. Charlson ME, Pompei P, Ales KL, MacKenzie CR,. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-83. (Pubitemid 17055592)
24. Romano PS, Roos LL, Jollis JG,. Adapting a clinical comorbidity index for use with Icd-9-Cm administrative data-differing perspectives. J Clin Epidemiol 1993; 46: 1075-9.
25. Schneeweiss S, Seeger JD, Maclure M, Wang PS, Avorn J, Glynn RJ,. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol 2001; 154: 854-64. (Pubitemid 33000813)
26. Herrinton LJ, Liu L, Fireman B, et al,. Time trends in therapies and outcomes for adult inflammatory bowel disease, Northern California, 1998-2005. Gastroenterology 2009; 137: 502-11.
27. Schneeweiss S, Korzenik J, Solomon DH, Canning C, Lee J, Bressler B,. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections. Aliment Pharmacol Ther 2009; 30: 253-64.
28. Glynn RJ, Schneeweiss S, Sturmer T,. Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin Pharmacol Toxicol 2006; 98: 253-9.
29. Aberra F, Lewis JD, Lichtenstein GR, Yang YX,. Proton pump inhibitor use and the risk of flare of inflammatory bowel disease. Gastroenterology 2006; 130: A649.
30. GPRD-The General Practice Research Database. Available at:. Accessed May 14, 2012.
31. Suissa S,. The case-time-control design: further assumptions and conditions. Epidemiology 1998; 9: 441-5. (Pubitemid 28298368)
32. Hill AB,. The environment and disease: association or causation? Proc R Soc Med 1965; 58: 295-300.
33. Williams J, Young W,. Inventory of Studies on the Accuracy of Canadian Health Administrative Databases. Technical report: Toronto, Canada: Institute for Clinical Evaluative Sciences (ICES), December 1996.
34. Jackson M,. Pharmacy management methods in Canada, including lower-cost therapy for heartburn. J Manag Care Pharm 2006; 12: 398-400.
35. Liu L, Allison JE, Herrinton LJ,. Validity of computerized diagnoses, procedures, and drugs for inflammatory bowel disease in a northern California managed care organization. Pharmacoepidemiol Drug Saf 2009; 18: 1086-93.
36. Piper JM, Ray WA, Daugherty JR, Griffin MR,. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med 1991; 114: 735-40.
37. Schneeweiss S,. A basic study design for expedited safety signal evaluation based on electronic healthcare data. Pharmacoepidemiol Drug Saf 2010; 19: 858-68.